Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%

Harvey B Dubiner1, Robert Noecker21Clayton Eye Center, Morrow, GA; 2Ophthalmic Consultants of Connecticut, Fairfield, CT, USABackground: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dubiner HB, Noecker R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ab7ada755665479cb113ce24127ffb07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab7ada755665479cb113ce24127ffb07
record_format	dspace
spelling	oai:doaj.org-article:ab7ada755665479cb113ce24127ffb072021-12-02T01:55:34ZSustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%1177-54671177-5483https://doaj.org/article/ab7ada755665479cb113ce24127ffb072012-03-01T00:00:00Zhttp://www.dovepress.com/sustained-intraocular-pressure-reduction-throughout-the-day-with-travo-a9597https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Harvey B Dubiner1, Robert Noecker21Clayton Eye Center, Morrow, GA; 2Ophthalmic Consultants of Connecticut, Fairfield, CT, USABackground: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily in the evening.Methods: The results of seven published, randomized clinical trials including at least one arm in which travoprost 0.004% was dosed once daily in the evening were integrated. Means (and standard deviations) of mean baseline and on-treatment IOP, as well as mean IOP reduction and mean percent IOP reduction at 0800, 1000, and 1600 hours at weeks 2 and 12 were calculated.Results: From a mean baseline IOP ranging from 25.0 to 27.2 mmHg, mean IOP on treatment ranged from 17.4 to 18.8 mmHg across all visits and time points. Mean IOP reductions from baseline ranged from 7.6 to 8.4 mmHg across visits and time points, representing a mean IOP reduction of 30%. Results of the safety analysis were consistent with the results from the individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the most common side effect.Conclusion: Travoprost 0.004% dosed once daily in the evening provides sustained IOP reduction throughout the 24-hour dosing interval in subjects with ocular hypertension or open-angle glaucoma. No reduction of IOP-lowering efficacy was observed at the 1600-hour time point which approached the end of the dosing interval.Keywords: travoprost ophthalmic solution 0.004%, intraocular pressure reductionDubiner HBNoecker RDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 525-531 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Dubiner HB Noecker R Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
description	Harvey B Dubiner1, Robert Noecker21Clayton Eye Center, Morrow, GA; 2Ophthalmic Consultants of Connecticut, Fairfield, CT, USABackground: The purpose of this study was to characterize intraocular pressure (IOP) reduction throughout the day with travoprost ophthalmic solution 0.004% dosed once daily in the evening.Methods: The results of seven published, randomized clinical trials including at least one arm in which travoprost 0.004% was dosed once daily in the evening were integrated. Means (and standard deviations) of mean baseline and on-treatment IOP, as well as mean IOP reduction and mean percent IOP reduction at 0800, 1000, and 1600 hours at weeks 2 and 12 were calculated.Results: From a mean baseline IOP ranging from 25.0 to 27.2 mmHg, mean IOP on treatment ranged from 17.4 to 18.8 mmHg across all visits and time points. Mean IOP reductions from baseline ranged from 7.6 to 8.4 mmHg across visits and time points, representing a mean IOP reduction of 30%. Results of the safety analysis were consistent with the results from the individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the most common side effect.Conclusion: Travoprost 0.004% dosed once daily in the evening provides sustained IOP reduction throughout the 24-hour dosing interval in subjects with ocular hypertension or open-angle glaucoma. No reduction of IOP-lowering efficacy was observed at the 1600-hour time point which approached the end of the dosing interval.Keywords: travoprost ophthalmic solution 0.004%, intraocular pressure reduction
format	article
author	Dubiner HB Noecker R
author_facet	Dubiner HB Noecker R
author_sort	Dubiner HB
title	Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
title_short	Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
title_full	Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
title_fullStr	Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
title_full_unstemmed	Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
title_sort	sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/ab7ada755665479cb113ce24127ffb07
work_keys_str_mv	AT dubinerhb sustainedintraocularpressurereductionthroughoutthedaywithtravoprostophthalmicsolution0004 AT noeckerr sustainedintraocularpressurereductionthroughoutthedaywithtravoprostophthalmicsolution0004
_version_	1718402795584880640

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%

Ejemplares similares